All In Biotech

Drug Trial Radar · NCT06549400

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed the MEX-DM-302 Study (ATLAS Study)

Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

176

Planned (sponsor's estimate)

Start

Sep 12, 2025

Primary completion

May 29, 2028

Study completion Jul 6, 2028

Sponsor

Lead sponsor
Lupin Ltd.Industry
Sponsor type
Industry
Collaborators
Lupin Atlantis Holdings S.A.
First posted
Aug 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label extension study intended to evaluate the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the parent study MEX-DM-302.

Conditions

  • Myotonic Dystrophy

Interventions

  • Mexiletine granules for prolonged-release oral suspensionDrug

    Mexiletine PR

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the long-term efficacy of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed MEX-DM-302 study.Time frame: 78 weeks

Locations

6 sites in 6 countries. Site status is shown where the registry gives one.

  • Laboratory for Muscle Diseases and Neuropathies

    Leuven, Belgium

  • Aarhus University Hospital

    Aarhus, Denmark

  • Ludug-Maximilians University

    München, Germany

  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata

    Rome, Italy

  • University Hospital of Madrid

    Madrid, Spain

  • University College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.